Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion type Assertion NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_head.
- NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion description "[First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_provenance.
- NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion evidence source_evidence_curated NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_provenance.
- NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion SIO_000772 20705357 NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_provenance.
- NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion wasDerivedFrom ctd_human-2016 NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_provenance.
- NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_assertion wasGeneratedBy ECO_0000218 NP26649.RAQdPQQbrYosWWtt4V0z9PGHJ8_LyJNHq4GeRlwa2tEZA130_provenance.